SCHEMBL17845560

SCHEMBL17845560

CC(=O)c1cn(-c2nnc(C)s2)c2cc(S(=O)(=O)NC3(C)CC3)ccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PARG Q86W56 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31122038 1.00 PARG (1.00) PARG
SCHEMBL31121999 0.89 PARG (1.00) PARG
SCHEMBL17845281 0.89 PARG (1.00) PARG
SCHEMBL31122032 0.87 PARG (1.00) PARG
SCHEMBL17845476 0.87 PARG (1.00) PARG
SCHEMBL31122015 0.81 PARG (1.00) PARG
SCHEMBL17845273 0.81 PARG (1.00) PARG
SCHEMBL31121987 0.80 PARG (1.00) PARG
SCHEMBL17845625 0.80 PARG (1.00) PARG
SCHEMBL23653161 0.80 PARG (0.67) PARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3907224-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2021-11-10 EP claimed
EP-3233845-B1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECH LTD (GB) 2021-07-21 EP claimed
US-20180194738-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-07-12 US claimed
EP-3233845-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2017-10-25 EP claimed
WO-2016097749-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-23 WO claimed
US-20250223266-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2025-07-10 US disclosed
US-12129236-B2 PARG inhibitory compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-10-29 US disclosed
US-20210380539-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-12-09 US disclosed
US-20210380539-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-12-09 US disclosed
EP-3907224-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2021-11-10 EP disclosed
EP-3233845-B1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECH LTD (GB) 2021-07-21 EP disclosed
EP-3233845-B1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECH LTD (GB) 2021-07-21 EP disclosed
US-20200165208-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2020-05-28 US disclosed
US-20200165208-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2020-05-28 US disclosed
US-20180194738-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-07-12 US disclosed
US-20180194738-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-07-12 US disclosed
US-20180194738-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-07-12 US disclosed
EP-3233845-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2017-10-25 EP disclosed
WO-2016097749-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-23 WO disclosed
WO-2016097749-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210380539-A1 PARG INHIBITORY COMPOUNDS PARP11, PARG, PARP16 PARG 2/4885
US-20180194738-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 PARG 1/4885
US-12129236-B2 PARG inhibitory compounds PARP11, PARG, PARP16 PARG 2/4885
US-20200165208-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 PARG 1/4885
US-20250223266-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 PARG 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.